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Current understanding of osteoarthritis pathogenesis and
relevant new approaches
Liping Tong1, Huan Yu
Di Chen1,2 ✉
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, Xingyun Huang1,2, Jie Shen

3

, Guozhi Xiao

4

, Lin Chen5, Huaiyu Wang6, Lianping Xing

7

and

1234567890();,:

Osteoarthritis (OA) is the most common degenerative joint disease that causes painful swelling and permanent damage to the
joints in the body. The molecular mechanisms of OA are currently unknown. OA is a heterogeneous disease that affects the entire
joint, and multiple tissues are altered during OA development. To better understand the pathological mechanisms of OA, new
approaches, methods, and techniques need to be used to understand OA pathogenesis. In this review, we ﬁrst focus on the
epigenetic regulation of OA, with a particular focus on DNA methylation, histone modiﬁcation, and microRNA regulation, followed
by a summary of several key mediators in OA-associated pain. We then introduce several innovative techniques that have been and
will continue to be used in the ﬁelds of OA and OA-associated pain, such as CRISPR, scRNA sequencing, and lineage tracing. Next,
we discuss the timely updates concerning cell death regulation in OA pathology, including pyroptosis, ferroptosis, and autophagy,
as well as their individual roles in OA and potential molecular targets in treating OA. Finally, our review highlights new directions on
the role of the synovial lymphatic system in OA. An improved understanding of OA pathogenesis will aid in the development of
more speciﬁc and effective therapeutic interventions for OA.
Bone Research (2022)10:60
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INTRODUCTION
Osteoarthritis (OA) is the most common debilitating disease, a
leading cause of disability, and is characterized by chronic pain
and whole arthropathies such as articular cartilage damage,
synovitis, subchondral bone remodeling and osteophyte formation.1–3 The prevalence of OA is increasing steadily due to the
aging population and worldwide obesity epidemic, which brings a
great social burden and imposes a major challenge on public
health.4–6 It is estimated that 303 million adults in the world were
affected, and in China, approximately 61.2 million people had OA
in 2017.7 Despite the high prevalence, no disease-modifying drugs
are currently available. The prescription drugs recommended by
international guidelines for OA management merely provide pain
relief for symptoms, and the long-term use of these drugs is often
associated with signiﬁcant side effects and toxicities.8,9
OA is a heterogeneous and complicated disease that affects
multiple joints, such as the knee, hip, lumbar facet joint, and
temporomandibular joint (TMJ).10,11 The risk factors involved in
knee and hip OA include genetics, aging, sex (female), race,
occupation (physical labor), obesity, hypertension, abnormal joint
strength lines, poor muscle strength, high-intensity exercise, and a
history of joint injury.12–18 These systemic susceptibility factors
and local factors can cause abnormalities in signaling pathways
and the related regulatory networks of key functional molecules
that transmit pain signals and regulate chondrocyte homeostasis,
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survival and death and ultimately lead to joint pain and
pathological cartilage changes in the synovial joint in OA. The
pathological mechanisms of OA are currently unknown. Epigenetic regulation is a newly emerging area associated with
alterations in catabolic and anabolic gene expression in osteoarthritic chondrocytes.19 Due to the lack of satisfactory management
for OA-associated pain, the mechanisms of OA-associated pain
and related signaling pathways remain unclear.20–22 Recent
ﬁndings have provided new insights into the roles of new forms
of regulated cell death and the synovial lymphatic system in the
pathogenesis of OA.23–26 To better understand the molecular
mechanisms and identify key target(s) for drug discovery and OA
treatment, we need to use novel approaches to comprehensively
investigate OA mechanisms using newly developed techniques
and methodologies. In this review, we will discuss the current
understanding of OA pathogenesis and some new approaches,
methods, and techniques that have been used in OA research in
recent years. First, we focused on the epigenetic regulation of OA,
with a particular focus on DNA methylation, histone modiﬁcation,
and microRNA regulation, which have been implicated in OA, and
potential epigenome-based therapeutics for OA, followed by a
summary of several key mediators in OA-associated pain,
including NGF, CGRP, CCL2/CCR2, and TNFα. We then introduced
several innovative techniques that have been and will continue to
be used in the ﬁelds of OA pathology and OA-associated pain,
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Fig. 1 Epigenetic regulation of osteoarthritis. Three types of epigenetic regulation of the molecular pathogenesis of OA. a DNA methylation is
catalyzed by DNMTs, and abnormal changes in DNA methylation occur in the promoter regions of related genes and signaling pathways in OA
chondrocytes. b Histone modiﬁcations included phosphorylation, methylation, acetylation, ubiquitination, and SUMOylation. Histone
acetylation is mainly mediated by HATs, and histone deacetylation is usually catalyzed by two types of enzymes: classic histone deacetylases
(HDACs) and sirtuins. Increased H3K4 methylation leads to catabolic responses mediated by iNOS and COX-2 expression in human OA
chondrocytes. The methylation of H3K9 increases Sox9 and mPGES-1 expression in human OA chondrocytes. c MiR-204/miR-211, miR-181a-5p,
miR-335-5p, and miR-93 inhibit Runx2, chondrocyte apoptosis, and the expression of catabolic and hypertrophic genes

such as CRISPR, scRNA sequencing, and lineage tracing. Next, we
discussed cell death regulation in OA pathology, including
pyroptosis, ferroptosis, and autophagy, as well as their individual
roles in OA and potential molecular targets for treating OA. Finally,
our review highlighted new directions on the role of the synovial
lymphatic system in OA.
EPIGENETIC REGULATION OF OSTEOARTHRITIS
In addition to genetic regulatory mechanisms, the role of
epigenetics has recently drawn increasing attention in the
regulation of chondrocyte homeostasis, as well as joint integrity
and health. Epigenetic regulation in mammalian cells typically
involves DNA methylation, histone modiﬁcation, and noncoding
RNA (miRNA and long noncoding RNA) regulation.27,28 Given that
epigenetics can govern several signaling pathways simultaneously
in a cell-dependent manner, it has been considered a potential
therapeutic target to manage OA.
DNA methylation
DNA methylation usually occurs on the cytosine residues of the
dinucleotide sequence CpG. The methylation process includes
adding a methyl group to the ﬁfth position of cytosine within a
CpG dinucleotide to form 5-methylcytosine (5mC), and this
process is mainly catalyzed by DNA methyltransferases (DNMTs)
(Fig. 1a). There are three bioactive catalytic DNMTs: DNMT1,
DNMT3a, and DNMT3b.29–31 DNMT1 serves as a maintenance
enzyme that binds hemimethylated DNA to maintain the DNA
methylation signatures across the genome during cell division and
proliferation. DNMT3a and DNMT3b are considered de novo
DNMTs since they can create new methylation patterns during
development.29–31 Several studies have established the crucial
role of DNMTs in embryonic development. Global ablation the
maintenance enzyme DNMT1 leads to embryonic lethality in mice.

Compared to DNMT3a, DNMT3b plays a more imperative role in
early embryogenesis, and knockout (KO) of DNMT3b causes
embryonic lethality with defects in craniofacial and rib cage
development,32,33 suggesting a potential regulatory role of
DNMT3b in chondrocytes and cartilage development.
In recognition of the roles of DNMTs in chondrocytes,
sequencing technology has been used to perform genome-wide
DNA methylation analysis has been conducted on healthy
individuals and OA patients.34,35 Not surprisingly, several wellknown pathways and key factors related to chondrocyte homeostasis have alterations in DNA methylation (5mC) in OA patients.
For example, a number of studies have shown abnormal changes
in DNA methylation in the promoter regions of related genes in
OA chondrocytes, including genes encoding extracellular matrix
molecules (e.g., Col2A1, CoL9A1, Col10A1, and Acan), matrixdegrading enzymes (e.g., MMP2, MMP3, MMP9, MMP13, Adamts4/
5), and key chondrogenic transcription factors (e.g., Sox9, Sox4,
and Runx2). Changes in DNA methylation have also been
identiﬁed in genes related to signaling pathways, including
growth factors [e.g., BMP7, sclerostin and growth differentiation
factor 5 (GDF5)], inﬂammatory factors (e.g., IL-1β, IL-8, C-terminalbinding proteins (CtBP), SOCS2 and LEP), and reactive oxygen
species (ROS)-related stress factors [e.g., superoxide dismutase
(SOD2) and inducible nitric oxide synthase (iNOS)].36–41 DNA
methylation is a dynamic process involving DNA methylation and
demethylation, and the DNA demethylation signature molecule 5hydroxy-methylcytosine (5hmC) has been identiﬁed in OA
chondrocytes.30,42 The 5hmC signature is generated by the
ten–eleven translocation cytosine dioxygenases TET1, TET2, and
TET3, which catalyze 5mC oxidation and generate 5mC derivatives, resulting in DNA demethylation at cytosine residues. Among
the three bioactive TETs, TET1 is one of the major enzymes
responsible for DNA methylation in chondrocytes and the
generation of 5hmC in OA chondrocytes. Moreover, in addition
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to the promoter regions of OA-related genes, irregular CpG
methylation in enhancer regions in OA chondrocytes has also
been reported.43–45 Although further investigation is needed, the
data from these studies indicate that DNA methylation can
regulate genes in proximity to enhancers in three-dimensional
geometry and in such a way that facilitates gene network
regulation associated with chondrocyte function, cartilage maintenance, and OA development.
Since alterations in DNA methylation have been found in OA
chondrocytes, most recent studies have been focused on
examining the underlying regulatory mechanisms and have
mainly focused on DNMTs. Zhu et al. recently demonstrated that
the expression of DNMT1 and DNMT3a was elevated in OA
cartilage from both OA patients and surgically induced murine OA
models. Mechanistically, the increases in DNMT1 and DNMT3a
resulted in the hypermethylation of the promoter region of
peroxisome proliferator-activated receptor-gamma (PPARγ), leading to suppression of PPARγ expression in OA chondrocytes. More
importantly, pharmacological inhibition of DNMT1/DNMT3a by
5-azacitidine could demethylate the PPARγ promoter, restore
PPARγ expression, and mitigate the severity of cartilage degeneration in mice, suggesting that the DNMT1/3a PPARγ axis is
crucial for OA development.46,47 In contrast, a reduction in
DNMT3b expression was observed in human and murine OA
cartilage.48 Speciﬁcally, the basal expression level of DNMT3b was
higher than that of DNMT1 or DNMT3a in healthy chondrocytes
and cartilage tissue; however, DNMT3b expression was signiﬁcantly decreased in murine OA models and OA patients, at least
partially due to an increase in the inﬂammatory (NF-κB) pathway.
Comprehensive genome-wide analysis revealed that DNMT3b
deﬁciency led to the induction of 4-aminobutyrate aminotransferase (Abat) through decreased methylation in the gene promoter,
which in turn stimulated tricarboxylic acid (TCA) metabolism and
mitochondrial respiration in DNMT3b loss-of-function chondrocytes. However, the increases in Abat expression and mitochondrial metabolism could be restored by the overexpression of
DNMT3b in chondrocytes, and importantly, DNMT3b gain-offunction induced a chondroprotective effect to maintain homeostasis and integrity of articular cartilage in the knee joint in
mice.48 Similar to that in the knee joint, the deleterious effect of
DNMT3b ablation was also observed in the temporomandibular
joint (TMJ). KO of DNMT3b stimulated β-catenin nuclear translocation in TMJ progenitor/stem cells; however, DNMT3b overexpression could normalize Wnt/β-catenin signaling and restore cell
homeostasis in vitro.49 Overall, recent studies showed the critical
role of DNMTs in OA development and suggested that DNMTs
may be new molecular targets for OA treatment in the clinic.
Histone modiﬁcation
Histone modiﬁcation is another type of epigenetic regulation in
mammalian cells. Histones are alkaline proteins that are typically
found in the nucleus and envelop DNA to assemble nucleosomes.
Histone modiﬁcation includes phosphorylation, methylation,
acetylation, ubiquitination, and SUMOylation50,51 (Fig. 1b). Histone
modiﬁcation usually regulated gene expression by altering
chromatin conformation and the ability of transcription factors
to access promoter and enhancer regions.50,51 Among these
histone modiﬁcations, methylation and acetylation are the two
mechanisms that are extensively studied in OA.52–61
The common site for histone methylation is the lysine (K)
residues of histone 3 (H3), and recent studies have examined
alterations in the epigenetic status of H3 in human OA
chondrocytes. On the one hand, it has been reported that the
methylation of H3K9 and H3K27 is increased in the promoter
region of the key anabolic gene Sox9 and is associated with
Sox9 suppression in human OA chondrocytes.57 On the other
hand, histone methylation has also been shown to be involved in
the regulation of the inﬂammatory response and catabolism in OA
Bone Research (2022)10:60

development. The Fahmi group evaluated the role of H3K9 and
H3K4 methylation in human OA chondrocytes54,55 and found that
under inﬂammatory conditions, the recruitment of the histone
demethylase LSD1 was enhanced, leading to a reduction in the
methylation level of H3K9 in OA chondrocytes, which in turn
stimulated the expression of microsomal prostaglandin E
synthase-1 (mPGES-1). Moreover, pharmacological blockade of
LSD1 could prevent IL-1β-induced H3K9 demethylation and the
induction of mPGES-1 in human chondrocytes.55 In addition to
H3K9 methylation, the Fahmi group investigated H3K4 methylation in human OA chondrocytes. In contrast to H3K9 demethylation, H3K4 methylation was increased by IL-1β in human
chondrocytes due to the induced expression of the histone
methyltransferase SET‐1A. Increased H3K4 methylation eventually
led to catabolic responses mediated by iNOS and COX-2
expression in human OA chondrocytes.54,62 These ﬁndings
suggest that histone methylation is involved in OA pathogenesis
through the regulation of anabolic and catabolic activities in
chondrocytes.
Similar to histone methylation, histone acetylation and deacetylation have also been extensively investigated in chondrocytes.52,53,56,58–61 In mammalian cells, histone acetylation is mainly
mediated by histone acetyltransferases (HATs), and histone
deacetylation is usually catalyzed by two types of enzymes: classic
histone deacetylases (HDACs) and sirtuins.63 The expression levels
of HDAC1 and HDAC2 are upregulated in OA chondrocytes and
are associated with the suppression of anabolic genes, such as
Col2a1 and Acan.52,58,60 In addition, Huber et al. showed that the
expression levels of HDAC1 and HDAC2 were upregulated in OA
synovial tissue, indicating an increase in histone deacetylation in
joint tissues.59 HDAC4 has also been extensively studied, although
its function is controversial. Lu et al. demonstrated that the
expression of HDAC4 was increased in OA cartilage compared to
normal cartilage, and a reduction in HDAC4 levels could
signiﬁcantly suppress the expression levels of Mmp1, Mmp3,
Mmp13, and Adamts4/5 in SW1353 chondrosarcoma cells.61
However, it has been shown that the expression of HDAC4 is
decreased in OA chondrocytes and increases the expression of
Runx2, Mmp13, Ihh, and Col-X. Therefore, HDAC4 may have
chondroprotective effects by inhibiting Runx2 and other OArelated genes.53 Moreover, correlation studies on Mmp13 and
HDAC7 showed that HDAC7 upregulation in OA cartilage was
related to enhanced Mmp13 production and ECM degradation.56
Since histone deacetylation is closely correlated with chondrocyte
homeostasis and OA, drugs related to HDACs have also been
investigated in vitro and in vivo to prevent cartilage degeneration
during OA progression. Inhibitors of HDACs, such as trichostatin
(TSA) and vorinostat, and HDAC knockdown by small interfering
RNAs have been effective in alleviating ECM degradation and
cartilage degeneration during OA progression.64–69 Furthermore,
several siRNAs against HDAC have been approved by the Food
and Drug Administration (FDA) in the US for cancer treatment,
including vorinostat, romidepsin, valproate and depakote.66
Further investigation is needed to determine if HDAC siRNAs
could be used for OA treatment.
Signiﬁcant progress has been achieved in clarifying the role of
Sirtuin 1 (SIRT1) in OA pathological progression.70–74 Several
cellular and animal studies have demonstrated that the SIRT1
protein is found in the nuclei of chondrocytes, as well as in
synovial cells. SIRT1 could regulate ECM protein expression in
chondrocytes, maintain homeostasis in chondrocytes and cartilage, and play a vital role in inhibiting catabolism, inﬂammation,
oxidative stress, and apoptosis in chondrocytes. SIRT1 expression
is decreased in OA chondrocytes.40,70–74 Importantly, several
studies have demonstrated that the activation of SIRT1 by
resveratrol or SRT1720 has chondroprotective effects against
cartilage destruction and OA progression. It has been shown that
treatment with resveratrol could signiﬁcantly enhance the gene
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expression of SIRT1 in chondrocytes, inhibit the IL-1β- or TNFαinduced inﬂammatory response, and prevent NO-induced apoptosis by regulating Bax and Bcl-2.75–79 In addition to resveratrol,
SRT1720, another SIRT1 activator, also showed a protective effect
against OA development. Intraperitoneal administration of
SRT1720 delayed OA progression in mice at least partially by
inhibiting the NF-κB pathway, as well as Mmp13 and Adamts5
expression, in chondrocytes.80 These studies suggest that SIRT1
activation may serve as an ideal therapeutic strategy for OA
treatment.
MicroRNA regulation of osteoarthritis
MicroRNAs (miRNAs) are small, single-stranded RNAs. The average
length of a miRNA is 22 nucleotides. MiRNAs negatively modulate
target gene expression by binding to the 3′-untranslated region
(UTR) of target genes.81–83 MiRNAs control approximately 50% of
the human transcriptome, and human DNA contains more than
45 000 miRNA target sites.84,85 A recent study demonstrated that
142 miRNAs were differentially expressed between damaged and
nondamaged OA articular cartilage. To determine the role of
miRNA-mediated gene regulation in OA pathology, 238 mRNAs
were found to be targeted by differentially expressed miRNAs in
OA cartilage using the 2 387 differentially expressed genes as a
background. Ten pathways were highly enriched, including the
pathways ‘positive regulation of GTPase activity’ and ‘neural
development’ associated with nerve growth factor (NGF).86 In
addition, several miRNAs have been shown to play speciﬁc roles in
OA progression (Fig. 1c).
Runx2 plays a key role in chondrocyte function.87 It has been
demonstrated that the deletion of one allele of the Runx2 gene in
Runx2 global-KO mice or deletion of both alleles of the Runx2 gene in
aggrecan-expressing cells in Runx2 conditional-KO mice (Runx2Agc1ER)
could signiﬁcantly delay OA progression caused by destabilization of
the medial meniscus (DMM) surgery.88,89 Our lab has identiﬁed that
miR-204 and miR-211 are two homologous miRNAs that play key
roles in the regulation of Runx2 expression in mesenchymal
progenitor cells.90 In the joint tissues of aging mice or OA mouse
models, the expression of miR-204/miR-211 was signiﬁcantly
decreased compared to that in young mice or sham-operated mice.
Deletion of miR-204/miR-211 in Prx1-expressing cells (targeting limb
mesenchymal progenitor cells) led to progressive OA development in
mice.91 Signiﬁcant upregulation of Runx2 protein expression and OA
marker genes was observed in miR-204/miR-211 double-KO mice.
Deletion of one allele of Runx2 in a miR-204/miR-211 double-KO
genetic background could signiﬁcantly reverse the OA phenotype
observed in miR-204/miR-211 double-KO mice.91 These ﬁndings
suggest that miR-204/miR-211 have chondroprotective effects during
OA development. Zhu et al. found that osteoclast-derived factors
coupled with exosomal packaging miRNA play a central role in bone
formation through paracrine and juxtacrine mechanisms that affect
osteoblast differentiation, suggesting that exosome-mediated delivery of miRNA may be a good strategy to treat OA.92
MiR-181a-5p is expressed in cartilage in the facet joint (FJ) and
is upregulated in human FJ OA and knee OA cartilage. The results
were conﬁrmed in the cartilage of rat FJ OA induced by injury and
knee traumatic OA. Treatment of rat or mouse chondrocytes with
miR-181a-5p antisense oligonucleotides (ASOs) attenuated the
expression of marker genes associated with chondrocyte catabolism and apoptosis. MiR-181a-5p ASO treatment reduced cartilage
damage, decreased catabolic and hypertrophic gene expression,
and inhibited apoptosis and type II collagen degradation in rat FJ
OA and mouse knee OA. In addition, the chondroprotective effect
of miR-181a-5p ASO was demonstrated in experiments using
human OA chondrocytes or ex vivo cartilage explants.93
MiRNA-335-5p and miR-93 have anti-inﬂammatory effects. It has
been shown that miRNA-335-5p activates AMP-activated protein
kinase (AMPK), which is associated with rapamycin (mTOR)
signaling and autophagy activation.94 MiRNA-335-5p inhibits OA

chondrocyte inﬂammation by activating autophagy.95 MiR-93
attenuates tumor necrosis factor (TNF)-α-, interleukin (IL)-1β- and
IL-6-induced inﬂammatory responses in chondrocytes.96 These
ﬁndings demonstrated that miRNAs are closely associated with
the regulation of OA development and progression.
OSTEOARTHRITIS-ASSOCIATED PAIN
Pain is the major symptom that prompts individuals with OA to
search for medical assistance. Pain is often associated with joint
damage in OA patients. However, pain may not always correlate
with structural changes in joint tissues. Sometimes there is a
separation between joint damage and pain. OA-associated pain
predominantly originates from the synovium and subchondral
bone of the joint. Except for normal articular cartilage, which lacks
nerve innervation, other tissues in the joint, including the
meniscus, ligament, tendon, and fat pad, all have abundant
sensory nerve innervation and can be the source of pain.
Nociceptors are stimulated by mechanical, chemical or thermal
noxious stimuli and transduce these noxious inputs into electrical
signals, which are transmitted along the dorsal root ganglion and
the dorsal horn of the spinal cord. Ultimately, ascending pathways
activate the higher brain center, leading to conscious awareness
of pain (Fig. 2). In contrast to fast pain, the persistent inﬂammatory
microenvironment in the OA joint causes peripheral and central
nerve sensitization with typical features of mechanical allodynia
and hyperalgesia around the joint.97,98 Despite the unclear
mechanism of nerve sensitization, joint replacement can reverse
this paresthesia, suggesting that the central nervous system is
highly plastic and that peripheral stimulation may be a major
intrinsic factor driving central nerve sensitization.99 A better
understanding of the mechanisms of OA-associated pain will help
in the diagnosis and treatment of OA.
NGF
Nerve growth factor (NGF) was ﬁrst identiﬁed because it induced
the growth of nerves.100 We now know that NGF is also associated
with intractable pain. NGF and its receptor tropomyosin receptor
kinase A (TrkA) are considered new targets for treating OAassociated pain.101 Anti-NGF antibodies and TrkA inhibitors have
been developed to suppress NGF/TrkA signaling.102 Interestingly,
local anesthetics can inhibit TrkA.103 Fasinumab and tanezumab
are humanized monoclonal antibodies against NGF. Patients with
symptomatic knee or hip OA were administered gradient doses of
fasinumab (1, 3, 6, or 9 mg) in a phase III clinical study.104 The
results demonstrated that all doses of fasinumab achieved
clinically important relief of pain compared with the placebo at
16 weeks. Destructive arthropathy was reported in one patient
who received 6 mg fasinumab. The latest phase III clinical study
with a 24-week follow-up period showed that tanezumab (5 and
2.5 mg) signiﬁcantly improved WOMAC pain and function and
Patient’s Global Assessment of OA with a 2.8% incidence rate of
rapidly progressive OA in the tanezumab 5 mg and 1.4% in
tanezumab 2.5 mg groups.105 Therefore, the underlying mechanisms of NGF-induced rapidly progressive OA should be carefully
and thoroughly examined. It has been reported that increases in
the angiogenic factor VEGF, the axonal promoting factor NGF/TrkA
and sensory neuronal distribution in individuals with FJ OA and
low back pain (LBP) have been detected. These ﬁndings were
associated with high expression levels of inﬂammatory cytokines,
pain-related molecules, and cartilage-degrading enzymes in the
degenerative cartilage of FJ.106 Seidel et al. reported that NGF was
predominantly distributed in damaged cartilaginous tissues (80%)
and in bone marrow (20%) in FJ OA, which was distinct from that
in the subchondral bone of knee OA.107 NGF and downstream
substance P are associated with cartilage pathology in FJ OA.
Despite the high risk of joint damage in knee OA, NGF inhibitors
have demonstrated good efﬁcacy in treating LBP. A phase III
Bone Research (2022)10:60
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clinical study of NGF antagonists in the treatment of chronic LBP
showed that fasinumab improved both LBP and function, and the
adverse effect of rapidly progressive OA only occurred in subjects
with accompanying peripheral OA.108

but not in males.118 These ﬁndings highlight the different pain
mechanisms in males and females with OA. Future studies should
determine the role of CGRP signaling in OA-associated pain in
females.

CGRP
Calcitonin gene-related peptide (CGRP) is expressed in primary
afferent nociceptive unmyelinated C-ﬁbers and is a critical factor
in migraine pain.109 CGRP is expressed in nociceptive C-ﬁbers.
CGRP is released from C-ﬁber terminals and sensitizes adjacent Aδ
nerve ﬁbers.110 Aδ nerve ﬁbers express calcitonin receptor-like
receptor (CLR) and receptor activity-modifying protein 1 (RAMP1).
These ﬁndings are consistent with recent observations that the
anti-CGRP antibody fremanezumab blocks induced ﬁring of Aδ
but not C-ﬁbers.111 CGRP receptors were also found in vascular
smooth muscle cells and joint tissues innervated by CGRP-positive
nerve ﬁbers.110 Although the source of OA-associated pain has not
been fully deﬁned, the detection of substance P (SP) and CGRP
ﬁbers in the synovial tissues in mice suggests that synovial tissue
may be the major source of pain during OA development.112 In
animal studies, intra-articular injection of CGRP caused mechanical
allodynia in naïve mice, and CGRP receptor antagonist and CGRP
neutralizing antibody treatment alleviated OA-associated pain.113
In OA patients, serum CGRP levels and the density of CGRPpositive nerve ﬁbers were highly correlated with OA-associated
pain symptoms and disease severity.114 However, a phase II
clinical trial showed that galcanezumab, a CGRP monoclonal
antibody, failed to relieve OA-associated pain.115 Interestingly,
accumulating evidence has shown sexual dimorphism in chronic
pain.116,117 Recently, Uchida et al. demonstrated that the
expression of CGRP and its receptor RAMP1 in the OA synovium
was markedly increased in women compared to men, and CGRP
expression was positively correlated with pain severity in females

CCL2/CCR2
The development of pain behavior is a complicated process
involving multiple signaling steps, including changes in the
expression and production of key mediators of pain in peripheral
organs and the expression of pain mediators in the sensory
neurons of the dorsal root ganglia (DRG).119,120 Some of this
evidence was observed in nerve injury animal models.121 It has
been shown that chemokines and chemokine receptors, especially
chemokine (C-C motif) ligand 2 (CCL2) and its receptor chemokine
(C-C motif) receptor 2 (CCR2) mediate pain behavior in the DRG
and spinal cord.119,122 The role of CCL2/CCR2 signaling in pain
mediation during OA development was determined using the
DMM OA mouse model. Malfait’s group performed longitudinal
studies to monitor pain behaviors and associated molecular
mechanisms in the sensory neurons that innervate the knee and
demonstrated the role of CCL2/CCR2 in the mediation of pain
behavior during OA development.123
It is well documented that chemokine–chemokine receptor axes
can excite DRG nociceptors by activating molecules such as TRP, and
sodium channels have been shown to modulate monocyte/
macrophage recruitment in multiple inﬂammatory diseases.119,124
However, the underlying cellular and molecular mechanisms of
CCL2/CCR2 signaling in OA-associated pain remain poorly understood. Raghu et al. found that CCL2- and CCR2-deﬁcient mice
exhibited reduced OA pathology and low local monocyte/macrophage inﬁltration in joints.125 Blocking CCL2/CCR2 signaling with
bindarit, a CCL2 synthesis inhibitor, and RS-504393, a CCR2
antagonist, markedly reduced macrophage accumulation and
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improved synovitis and cartilage lesions in mouse OA. A recent
study demonstrated that CCL2/CCR2 signaling caused knee
hyperalgesia through direct activation of CCR2 on sensory afferents
in peripheral joints.126 Therefore, CCL2/CCR2 signaling involves both
peripheral and central mechanisms that contribute to OA-associated
pain. Targeting CCL2/CCR2 signaling in the local joint and in the
innervating dorsal root ganglia, as well as the dorsal horn, are
potential strategies for treating OA-associated pain.
TNF-α
Inﬂammation can be a major cause of joint damage and OAassociated pain. Although central nociceptive pathways are
involved in OA-associated pain, the interaction of the immune
system with nociceptive neurons is critical for inﬂammatory pain.
Following joint damage and peripheral nerve injuries during OA
development, neurons release chemokines, such as CCL2 and
CX3CL1, and other immune mediators, such as colony-stimulating
factor 1 (CSF-1).127–129 These factors activate microglia and
astrocytes, which can release proinﬂammatory cytokines, including TNF-α, IL-1β, and IL-6, the chemokine CCL2, excitatory amino
acids (EAAs), and nitric oxide (NO).128,130–132 Neurons in the dorsal
horn of the spinal cord express receptors for many of these
inﬂammatory factors and cytokines, including TNF-α, IL-1β, IL-6,
and IL-17.133,134 Activating neuronal cytokine receptors could
modify neuronal function. For example, it has been shown that
TNF-α and IL-1β promote excitatory synaptic transmission and
inhibit inhibitory synaptic transmission in neurons in the spinal
cord.135,136
Previous studies have demonstrated that TNF-α is a major
proinﬂammatory cytokine and is closely associated with OA
pathogenesis; however, clinical trials of patients with hand OA did
not achieve good results.137 In a multicenter study, patients with
inﬂammatory hand OA that ﬂared after NSAID washout were
enrolled for anti-TNF-α therapy. Etanercept did not show notable
pain relief compared with placebo after 24 weeks of treatment in
erosive OA patients.138 In the HUMOR trial, subcutaneous injection
of adalimumab did not improve VAS pain scores or OA-related
pathology, such as synovitis and bone marrow lesions, in patients
with erosive hand OA.139 TNF-α has two high-afﬁnity and speciﬁc
receptors: TNFR1 and TNFR2. These two receptors are differentially
expressed and seem to have distinct functions. TNFR1 is expressed
by nearly all cell types and primarily mediates inﬂammation, while
TNFR2 is expressed by certain cells, such as neural cells and
vascular endothelial cells, and inhibits inﬂammation in inﬂammatory arthritis and neurodegenerative diseases, as well as cardiac
diseases. A recent study demonstrated that TNFR2 is also
expressed in chondrocytes and that the activation of progranulin
(PGRN)/TNFR2/14-3-3ε signaling in chondrocytes alleviates OAassociated pain and protects against OA.140 These ﬁndings
suggest that TNFR2 signaling is a promising target for treating
OA-associated pain and pathology (Fig. 2).
CRISPR TECHNOLOGY
The ability to manipulate genetic information is critical for
studying gene function and revealing biological mechanisms.
Advances in genome and transcriptome engineering technologies have sparked a new revolution for life science research in
the past decade.141 CRISPR/Cas systems are derived from the
prokaryote adaptive immune system that protects bacteria and
archaea against invading genetic materials.142 These systems
consist of clustered regularly interspaced short palindromic
repeats (CRISPR) and multiple genes encoding CRISPRassociated (Cas) proteins that adjoin the CRISPR array.143 A
diverse range of CRISPR/Cas systems has been used to target
and modulate nucleic acids. Whole CRISPR/Cas systems rely on
CRISPR RNA (crRNA) or on a single guide RNA (sgRNA) for target
recognition. The spacer part of the crRNA or sgRNA hybridizes

with the targeting sequence that is upstream of the protospacer
adjacent motif (PAM) or protospacer ﬂanking sequence (PFS),
and then the Cas cleaves the target DNA or RNA.144,145 Thus, by
designing crRNA or sgRNA containing proper spacer sequences,
CRISPR/Cas systems can achieve cleavage at any locus of
interest next to a PAM or a PFS.
Of the current emergence genome editing tools, the most
widely used is the class of RNA-guided endonucleases known as
Cas9 (Fig. 3a). Speciﬁcally, Streptococcus pyogenes Cas9 (SpCas9)
was the ﬁrst to be reprogrammed for genome editing in
eukaryotic cells, and it remains the most commonly used
Cas9.146 Cas9 generates DNA double-strand breaks (DSBs) that
activate the DNA damage response and induce repair by the
endogenous pathways: nonhomologous end joining (NHEJ) or
homologous directed repair (HDR).147 NHEJ is an error-prone
repair process that leads to the generation of small insertions or
deletions (Indels).148 Thus, it is useful for silencing gene expression
by disrupting the protein reading frame.149 HDR is an error-free
repair process that corrects pathogenic mutations by using a
repair DNA template to stimulate homologous recombination.
HDR can be used to introduce the desired change by providing
donor DNA that contains a homology sequence to the fractured
target site, such as gene site-directed mutation or the insertion of
a larger fragment of DNA.150 It is important to note that NHEJ is
markedly more active than HDR. Therefore, increasing the
efﬁciency of HDR following Cas9-mediated DSBs is widely pursued
to fully examine the potential of genome editing to introduce
accurate genomic modiﬁcation.151,152
CRISPR/Cas9 technology has been widely used in the
construction of plant, animal, and cellular models.153–155 A
representative example of this is the generation of osteocalcinknockout rats.156 The osteocalcin-null rat models showed
increased trabecular bone and improved biomechanics. IL-1β
is a proinﬂammatory cytokine that induces the expression of
many genes related to OA, such as tumor necrosis factor-alpha
(TNF-α).157 It is interesting to note that exposure of human
articular chondrocytes (hAC) to TNF-α leads to increased levels
of IL-1β expression.158 Karlsen and colleagues silenced the IL-1β
cytokine receptor (IL1-R1) and simultaneously inserted a
puromycin-resistance gene into hACs with CRISPR/Cas9 technology. In their study, unedited cell lines showed increased
inﬂammation when exposed to recombinant IL-1β. Conversely,
the IL1-R1-deﬁcient cell line did not cause an obvious
inﬂammatory response.159 These models provide a platform
for understanding fundamental molecular mechanisms that are
related to healthy joint tissue and further exploring potential
targets of OA treatment. A particularly inspiring direction is the
development of Cas9 as a therapeutic molecule for curing
hereditary diseases.160,161 Delivery tools for gene-editing
molecules include adeno-associated viral vectors, lentiviral
vectors, lipid nanoparticles, and other nonviral vectors.162
Clinical trials aimed at evaluating the ability of CRISPR/Cas9 to
safely correct genetic diseases such as sickle cell disease
(NCT03745287), β-thalassemia (NCT03655678), and Leber congenital amaurosis type 10 (NCT03872479) have been initiated.
We recently investigated the roles of NGF, IL-1β, and MMP13 in
OA development by deleting these genes in joint tissues using
the CRISPR–Cas9 technique163–165 (Fig. 3c). The key ﬁndings of
this study were that joint tissue NGF deﬁciency could efﬁciently
eliminate joint pain but not structural OA damage, and deletion
of these three potential harmful OA genes for OA (NGF, IL-1β,
and MMP13) had a strong chondroprotective effect, inhibiting
pathological damage of joint tissues and alleviating joint pain
caused by destabilization of medial meniscus (DMM) surgery.166
The ﬂexibility, programmability, and high efﬁciency of CRISPR/
Cas9 technology have promoted genome editing in studies
ranging from fundamental science to translational medicine.
Perhaps CRISPR/Cas9 could be used to treat OA.
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Fig. 3 CRISPR/Cas systems have been used for gene editing and treating OA. a Cas9 generates DNA double-strand breaks that activate the
DNA damage response and induce repair through various endogenous pathways: nonhomologous end joining (NHEJ) or homologous
directed repair (HDR). b Cas13 cuts the target RNA via intrinsic RNase activity. c CRISPR–Cas9-mediated NGF, IL-1β, and MMP13 deletion and
CRISPR–Cas13-mediated ihh knockout were used for OA treatment

Traditional genomic editing relies on DSB repair pathways,
which can cause various side effects in cells, such as large
deletions and complex rearrangements around the target, the
emergence and expansion of p53-inactivating mutations, and
chromosomal truncations.167–169 The risks associated with
permanent DNA modiﬁcations raise serious safety concerns
regarding the clinical applications of the CRISPR/Cas9 system.
The emergence of the CRISPR/Cas13 family, which cuts a target
RNA via intrinsic RNase activity, provides another promising
method for gene therapy145,170 (Fig. 3b). Currently, type A, type
B, type D, type X, and type Y Cas13 family members have been
identiﬁed.171,172 Cas13 targeting has some advantages compared to Cas9; it avoids inducing DNA damage to cells and is
theoretically reversible, since it affects RNA. In 2020, Yang and
colleagues used CasRx, which is derived from type D, to
knockdown Pten, Pcsk9, and lncLstr in mouse hepatocytes and
successfully modulate complex metabolic networks.173 The
researchers also targeted vascular endothelial growth factor A
(VEGFA), an angiogenic growth factor, and suppressed choroidal neovascularization (CNV) in a mouse model of age-related
macular degeneration (AMD).174
It has been reported that overactivation of the Indian hedgehog
(Ihh) pathway in chondrocytes strengthens the severity of OA.175
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However, knockout of the Ihh gene is undesirable for OA
treatment since it is lethal in animals.176 In this context, Cas13mediated Ihh knockdown will be a more desired choice through
cartilage-speciﬁc delivery in adults. OA-related factors, including
matrix metalloproteinases (MMPs), inﬂammatory cytokines, and
growth factors, could be potential targets of the CRISPR/
Cas13 system163,164 (Fig. 3c).
SINGLE-CELL RNA SEQUENCING
Synovial tissues mainly contain two types of cells: synovial
ﬁbroblasts (SFs) and macrophages. During OA initiation,
synovial cells interact with macrophages/leukocytes and
release inﬂammatory cytokines, leading to OA development.
Thus, to determine the key genes in SFs involved in OA
occurrence, it is important to identify subpopulations of cells
and associated genes in OA development. RNA sequencing
(RNA-seq) and single-cell RNA sequencing (scRNA-seq) could
be very useful to fulﬁll this task. Through these approaches, we
may be able to identify key genes associated with OA initiation
and progression.
scRNA-seq data of SFs in OA in the GEO database were analyzed.
In these studies, the genes and pathways associated with OA
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Fig. 4 Lineage tracing technique. a–c Col2-expressing cells label a subpopulation of chondrocytes which could migrate to bone marrow
underneath the growth plate and transdifferentiate into progenitor cells. a Col2-CreER mice were generated and bred with ROSAmT/mG reporter mice
or ROSAtdTomato reporter mice. b Tamoxifen was intraperitoneally injected to the 2-week-old Col2-CreER; ROSAmT/mG mice or Col2-CreER; ROSAtdTomato
mice for 5 consecutive days (1 mg per 10 g body weight) and mice were sacriﬁced at 4-week-old. c Col2-expressing cells were detected in articular
chondrocytes, growth plate chondrocytes and cells located in bone marrow underneath the growth plate. d DNA barcoding technology was used for
cell lineage tracing. Figure 4a, b256 and Fig. 4c257 were cited from our previous publications.

development were analyzed and identiﬁed by bioinformatics
methods. In one of these studies, scRNA-seq data of SFs in OA
patients were subjected to bioinformatics analyses, and OA-related
genes were identiﬁed as those encoding ECM proteins and immune
and cell adhesion molecules. Fibronectin 1 was identiﬁed as a key
protein with functional changes during OA development.177
One comprehensive study was conducted using human OA
cartilage at different stages to analyze the single-cell proﬁles of OA
chondrocytes. This study shows a transition from proliferating
chondrocytes to prehypertrophic and hypertrophic chondrocytes
(HTCs) and identiﬁed a new subpopulation of cells among HTCs.
The researchers also identiﬁed novel marker genes for cartilage
progenitor cells and showed the association of these progenitor
cells with ﬁbrocartilage chondrocytes through bioinformatics
analysis.178 A recent scRNA-seq study demonstrated that two
marker genes (Col6a3 and ACTG1) were highly expressed in
synovial tissues and were involved in focal adhesion. These two
genes were upregulated during OA development, suggesting their
roles in OA progression.179
LINEAGE TRACING
Lineage tracing has been successfully used in skeletal development studies. Several mouse models, such as Osx-CreER mice,
Col2-CreER mice and Nestin-CreER mice, have been generated and
used in lineage tracing studies. These mice were bred with

ROSA26R-LacZ reporter, ROSAtdTomato or ROSAmT/mG reporter mice.
The differentiation and migration of mesenchymal progenitor cells
could be monitored by examining reporter activity and the fates
of stage-selective subsets of osteoblast lineage cells. These studies
revealed that perichondrial precursors, Osx-expressing cells or
Col2-expressing cells (Fig. 4a–c) could migrate and differentiate
into trabecular osteoblasts, osteocytes, and stromal cells inside the
developing bone, and some of these cells were also associated
with invading blood vessels and pericytes.180 These cells can
maintain their progenitor cell phenotype into late postnatal life.181
Based on lineage tracing studies, we also learned that resting zone
chondrocytes in the growth plate could migrate into the bone
marrow underneath the growth plate and dedifferentiate into
mesenchymal progenitor cells. These cells could further differentiate into osteoblasts, which are involved in bone formation.182
In addition, these dedifferentiated progenitor cells could also
differentiate into adipocytes and regulate osteoclast formation.183,184 Although lineage tracing techniques have been
successfully used in skeletal development studies, we know very
little about how mesenchymal cells differentiate into synovial cells
and articular chondrocytes under normal physiological or
osteoarthritic conditions.
However, current lineage tracing approaches poorly reﬂect
whole and complex organisms. In the past decade, the emergence
and development of gene editing and DNA barcoding
technologies have brought several advantages for cell lineage
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Fig. 5 Pathways of pyroptosis, ferroptosis, and autophagy. a Many factors trigger assembly of the NLRP3 inﬂammasome, followed by
activation of caspase-1 or caspase-11/4/5, which cleaves the gasdermin D (GSDMD) protein and pro-IL-1β and pro-IL-18, resulting in the
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tracing185,186 (Fig. 4d). In 2016, McKenna and colleagues
performed a combination of CRISPR/Cas9-based genome editing,
DNA barcoding, and single-cell sequencing to read cell lineage
information for the ﬁrst time.187 This technique has been called
‘dynamic lineage tracing’.188,189 First, this approach marks
individual cell lineages by inserting a compact DNA sequence
into the genome. Then, the recombinase or CRISPR system is
delivered or activated in cells to trigger barcode modiﬁcation to
increase the diversity of barcode sequences in cells during
development. Finally, the barcode information is collected and
analyzed to reconstruct a cell lineage tree by single-cell
sequencing.190
CELL DEATH REGULATION
Cell death is a fundamental physiological process in multicellular
organisms that maintains homeostasis during embryonic development and responds to harmful environmental stimuli to
eliminate superﬂuous, damaged, senescent, and potentially
harmful cells.191,192 In contrast, programmed cell death is
regulated by a complex and delicate genetic process and is
beneﬁcial for tissue homeostasis and immune responses.193,194
For many years, apoptosis has long been considered the only
form of regulated cell death, and necrosis was considered an
unregulated cell death process. In the past two decades, the
existence of new forms of cell death has been established.
Several new forms of regulated cell death, such as pyroptosis,
necroptosis, ferroptosis, parthanatos, mitochondrial permeability
transition (MPT)-dependent necrosis, autophagy, and pyronecrosis, have been identiﬁed and characterized.195,196 Recent
ﬁndings have provided new insights into the mechanisms of
Bone Research (2022)10:60

regulated cell death and in vivo relevance to OA pathology and
suggest that regulated cell death could have a signiﬁcant impact
on OA pathology (Fig. 5).
Pyroptosis
Pyroptosis was identiﬁed by D’Souza et al. in 2001 and described
as proinﬂammatory programmed cell death, which is different
from apoptosis.197 This process induces cell lysis and causes the
massive release of cellular contents and proinﬂammatory factors,
contributing to the development of many autoimmune and
inﬂammatory diseases. Pyroptosis is triggered by the
inﬂammasome-driven activation of caspase-1 or caspase-11/4/5,
which cleaves the gasdermin D (GSDMD) protein,198–200 separating its N-terminal pore-forming domain (GSDMD-NP) from the
C-terminal repressor domain (GSDMD-CR).201,202 GSDMD-NP binds
to the inner acidic phospholipids of the plasma membrane and
forms pores in the plasma membrane, resulting in the release of
IL-1β and IL-18. These proinﬂammatory cytokines are then
processed by caspase-1 and induce pyroptotic cell death (Fig. 5a).
Excessive inﬂammation in chondrocytes plays a vital role in
chondrocyte survival, leading to OA pathology. One study
demonstrated that acid-sensitive ion channel 1a mediates
chondrocyte pyroptosis in an adjuvant-induced arthritis model
in rats.203 Another study revealed that NLRP3 was activated in an
experimental OA model, and the NLRP3 inhibitor CY-09 protected
against OA development.204 Our previous studies have demonstrated that loganin and morronside attenuate OA development
by inhibiting chondrocyte pyroptosis.26,205 As the main effector
cells of synovial ﬁbrosis in knee OA, ﬁbroblast-like synoviocyte
pyroptosis was reported to be mediated by NLRP1 and NLRP3
inﬂammasomes in knee OA, and an increase in HIF-1α may
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exacerbate synovial ﬁbrosis by promoting ﬁbroblast-like synoviocyte pyroptosis.206 The molecular mechanisms underlying pyroptosis in OA need to be further investigated.
Ferroptosis
Ferroptosis is a novel form of programmed cell death that is
driven by iron-dependent lipid peroxidation but is morphologically and biochemically different from other types of regulated cell
death.207,208 Dixon et al. ﬁrst reported and named this nonapoptotic cell death, which is characterized by aberrant accumulation of lipid reactive oxygen species (ROS), in 2012.209 Ferroptosis
can be regulated by different metabolic pathways, including redox
and iron homeostasis, mitochondrial activity and the metabolism
of amino acids, lipids, and sugars.210,211 GPX4 is the key regulator
of ferroptosis. Ultimately, GPX4 inactivation results in irondependent intracellular accumulation of lethal levels of lipid
hydroperoxides (Fig. 5b).
Many pathophysiological processes are involved in the induction of ferroptosis, such as neurodegeneration, ischemia/reperfusion injury, and stroke.212,213 In OA, inﬂammation and metabolic
factors are two important contributors associated with OA
cartilage loss and disease symptoms.214,215 A recent report
demonstrated that chondrocyte ferroptosis was involved in OA
progression.216,217 It has been demonstrated that the induction of
chondrocyte ferroptosis increases MMP13 expression while
decreasing collagen II expression. Intra-articular injection of
ferrostatin-1, a ferroptosis inhibitor, prevented OA progression.
Interestingly, several signaling pathways related to OA could
regulate ferroptosis. Hippo-Yap signaling increases ferroptosis in
cancer cells.218–220 Energy stress-mediated AMPK signaling inhibits
fatty acid synthesis and negatively regulates ferroptosis.221,222
Hypoxia signaling promotes ferroptosis by activating hypoxiainducible factors (HIFs) and increasing the production of ROS.212
This evidence suggests that pharmacological modulation of
ferroptosis may hold great potential for the treatment of OA.
Autophagy
Autophagy is a highly conserved process that results in lysosomal
degradation of bulk cytoplasmic contents, abnormal macromolecule aggregates, and excess or damaged organelles, which is
essential for cellular homeostasis.223,224 In eukaryotic cells,
autophagy often refers to macroautophagy, which is characterized
by the generation of double-membraned vacuoles called autophagosomes, which sequester cytoplasmic components before
delivering them to the lysosome for degradation. The canonical
formation of autophagosomes involves the following steps:
initiation, nucleation, elongation and closure and recycling (Fig.
5c). Each step depends on a unique molecular mechanism. The
important components of the autophagy signaling pathway
include the ULK1 complex, the BECLIN1-PtdIns3KC3-ATG14L
complex, WIPIs, ATG12-ATG5, LC3-PE conjugation systems, and
ATG9.223 Activating mTOR suppresses autophagy and Akt and
AMPK signaling, and inhibiting mTOR promotes AMPK and
p53 signaling.225–227 In addition, hypoxia, reactive oxygen species
and nutrient and energy deprivation can generally activate
autophagy.
It is well known that OA is an aging-related disease associated
with the accumulation of damaged macromolecules, which leads
to chondrocyte dysfunction and death. Previous studies have
reported that reduced expression of ULK1, Beclin1, and LC3 was
observed in human OA and aging-related and surgically induced
OA in mice, indicating a deﬁciency in autophagy regulation in OA
chondrocytes.228 Recent studies have demonstrated that autophagy activation protects against mitochondrial dysfunction in
human chondrocytes and that loss of function of mTOR in
cartilage tissue protects mice from developing OA by upregulating
autophagy.229,230 Thus, the use of therapeutics targeting the
autophagy signaling pathway is a potential strategy for OA

treatment. Certain autophagy-enhancing drugs have been shown
to attenuate OA cartilage degeneration. Local intraarticular
injection of rapamycin reduces mTOR expression and delays
articular cartilage degeneration in a DMM-induced murine model
of OA.42,231 Currently, a phase III clinical trial (NCT02905799) is
being conducted to determine the efﬁcacy of resveratrol for OA
treatment.
SYNOVIAL LYMPHATICS IN OSTEOARTHRITIS
Currently, there is no effective therapy for OA. The identiﬁcation of
new pathways and mechanisms responsible for the initiation and
progression of OA will advance the development of new therapies
for OA. Cartilage-derived catabolic factors accumulate in the
synovium of OA joints, but how these catabolic factors are cleared
is currently unknown.
The synovial lymphatic system (SLS)
Lymphatic vessels (LVs) are composed of capillary and collecting
vessels.232 Capillary LVs have a thin layer of lymphatic endothelial
cells (LECs) that express LV endothelial hyaluronan receptor 1 and
podoplanin, a transmembrane glycoprotein.233 Collecting LVs are
covered with lymphatic muscle cells that have phenotypic
features of both striated and vascular smooth muscle cells.234,235
However, a recent lineage tracing study revealed that popliteal
lymphatic muscle progenitor cells are distinct from skeletal (Pax7+
and MyoD+) and vascular muscle progenitors (Prrx1+ and NG2+)
during development and after postnatal Day 10 and are derived
from a previously unknown Pax7-/MyoD-/Prrx1+/NG2− muscle
progenitor.236 Lymph cells are propelled by alternating contraction and relaxation of lymphatic muscle cells to draining lymph
nodes (DLNs) and eventually to the venous circulation.237,238
Using a combination of near-infrared and indocyanine green
lymphatic imaging239–244 to monitor LV contraction and clearance
from joints to DLNs and immunoﬂuorescence staining/whole slide
imaging to identify and qualify LVs in mouse joints,245,246 we
reported that LVs are present in the synovium and surrounding
soft tissues in the knee joint, including the joint capsule, fat pads,
ligaments, and muscles. Knees drain to iliac LNs (ILNs), while
ankles (footpad) drain to popliteal LNs (PLNs) via collecting
LVs.241,245,247 These LVs are therefore named the synovial
lymphatic system (SLS), which consists of initial LVs in the
synovium and the surrounding soft tissues, DLNs, and collecting
LVs (large vessels whose contractions move lymph from initial LVs
to DLNs).248
The SLS in arthritis
The role of the SLS in murine and human rheumatoid arthritis (RA),
which is an autoimmune disease, has been actively studied in the
past 15 years, and the results reveal its importance in RA
progression and treatment (for details please see the review).248
This conclusion is based on several reports. (a) In RA mouse
models, including collagen-induced arthritis mice, KRN transgenic
mice and TNF transgenic mice, SLS draining correlates with the
progression of joint damage and is improved by drugs that reduce
RA pathology. (b) Stimulation of lymphangiogenesis by vascular
endothelial growth factor C (VEGF-C) and its receptor (VEGFR3)
attenuates RA joint damage, and inhibiting lymphangiogenesis
with a VEGF inhibitor accelerates RA joint damage. VEGF-C is
considered a lymphatic-speciﬁc growth factor because VEGFR3 is
mainly expressed by LECs. (c) More recently, altered LV anatomy
and markedly decreased lymph clearance were observed in the
affected hands of individuals with active RA,249 providing strong
evidence for the involvement of the SLS in human RA. OA patients
suffer from similar joint stiffness and pain as RA individuals, but
these types of arthritis are very different in origin. OA is associated
with long-term mechanical wear and tear on the cartilage during
natural aging, while RA is an autoimmune disease. The
Bone Research (2022)10:60
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involvement of the SLS in human and murine RA has been well
studied; however, only a few reports have focused on the
SLS in OA.
SLS studies in OA. Early case studies reported that a radiolabeled
tracer was cleared to DLNs after being injected into a normal joint,
and it accumulated in the synovial space following injection into
an OA joint of the same individual.250 These ﬁndings suggested
that the injected tracer was removed from the synovial space via
LVs in normal joints and that this process was impaired in OA
joints.
A more systemic clinical study was performed by immunostaining 60 knee samples taken from severe knee OA patients during
total knee replacement surgery. Sixty postmortem control knees
were stained with podoplanin, a commonly used marker for LECs,
and LV density and LEC fractional area were quantiﬁed. Similar
results were obtained as those found in a mouse study.245 LVs
were detected in synovial tissue but not in subchondral bone. OA
samples exhibited lower LV density and fewer LEC fractional areas
than nonarthritic controls. In individuals with OA, low LV density
and LEC fractional areas were associated with clinically detectable
effusion but not with radiological or histological severity of OA
tissue damage. These ﬁndings support a pathogenic role of
synovial drainage via LVs in effusion as a clinical sign of synovitis
in OA.251
SLS studies in OA mouse models. To investigate whether the SLS
contributes to OA pathology and identify the potential mechanisms involved, we examined lymphatic drainage in WT mice with
posttraumatic OA (PTOA) and found that lymphatic drainage was
decreased in PTOA joints.245 VEGFR3-neutralizing antibody administration further reduced synovial lymphatic drainage and
accelerated joint tissue damage. Synovial LECs that were isolated
from PTOA joints based on podoplanin expression had increased
expression of inﬂammatory factors. Interestingly, more macrophages, mainly M1 macrophages, were located adjacent to
podoplanin+ LVs, and these M1 macrophages stimulated inﬂammatory gene expression in LECs in cocultures. Intra-articular
injection of bortezomib increased lymphatic drainage and
decreased the number of M1 macrophages in synovial tissue,
resulting in decreased cartilage loss. Thus, local joint delivery of
bortezomib or other anti-inﬂammatory drugs may restore synovial
lymphatic function in individuals with posttraumatic knee OA.25
OA develops primarily as a result of aging. Interestingly,
lymphatic dysfunction in aging has been recognized recently. In
2018, Mesquita et al. reported that in the brain, meningeal LVs
remove cerebrospinal ﬂuid macromolecules. Disruption of meningeal LVs in mouse models of Alzheimer’s disease promoted
amyloid deposition and exacerbated parenchymal amyloid
accumulation.252 Treatment of aged mice or mice with Alzheimer’s
disease with VEGF-C enhanced meningeal lymphatic drainage.
This study also showed decreased VEGFR3 signaling in meningeal
LECs isolated from aged mice. Thus, it is likely that VEGF-C/VEGFR3
downregulation represents a new underlying mechanism for agerelated lymphatic dysfunction.
Arthritogenic matrix metalloproteinase (MMP13) is cleared from
arthritic joints via the SLS
The SLS drains large molecules to DLNs. MMP13 is a critical
catabolic enzyme in both RA and OA arthritic joints that destroys
cartilage. Despite some beneﬁcial effects on arthritic models,253
MMP13 inhibitors have shown no greater advantages than
placebo in OA clinical trials, and notable musculoskeletal toxicity,
such as arthralgia and edema, was observed.254 To examine
whether the MMP13 protein can be cleared from arthritic joints to
DLNs via the SLS, we examined MMP13 protein and gene
expression in the synovium and corresponding DLNs by
immunohistochemistry (IHC) and RT–qPCR in PTOA or TNF
Bone Research (2022)10:60

transgenic (TNF-Tg) mice. MMP13 protein and mRNA expression
was signiﬁcantly higher in the synovium of PTOA and RA mice
than in controls. MMP13 protein levels in the DLNs of arthritic
mice were also markedly upregulated compared to those of
control mice, but no differences in mRNA levels were detected
(Fig. 6). The IHC results showed that MMP13 was expressed on
only articular chondrocytes in mice with PTOA and the synovium
in TNF-Tg mice (Fig. 6a, d). Consistently, the DLNs in these two
established mouse models exhibited robust immunoreactivity,
while no MMP13 expression was detected in the DLNs of control
mice without arthritis (Fig. 6a–e). Interestingly, we only detected
the expression of Mmp13 mRNA in the knee synovium but not in
DLNs (Fig. 6c, f). Given the high MMP13 protein expression in
DLNs without de novo synthesis, these data demonstrate that
matrix metalloproteinases expressed in the DLNs came from the
afferent arthritic knee and was translocated via SLS clearance.
Furthermore, the SLS plays an important role in the efﬁcient
clearance of catabolic large molecules that lead to cartilage
breakup, which is critical for protecting against arthritic damage.
Thus, improving lymphatic clearance is a viable strategy for
arthritis treatment.
Most SLS studies are focused on the association between the
SLS and arthritis during disease progression and the response to
treatment. For example, SLS dysfunction becomes more severe
with arthritis progression, and drugs that attenuate joint damage
are often associated with the restoration of SLS function. In these
studies, the speciﬁc involvement of LVs in arthritis is evidenced by
LEC-speciﬁc manipulation, including the use of VEGF-C- and
VEGFR3-neutralizing antibodies or signaling inhibitors. Since the
VEGF-C/VEGFR3 signaling pathway affects processes than those of
LECs, such as macrophage activation,255 using a genetically
modiﬁed mouse model with LEC-speciﬁc manipulation is needed
to provide more direct evidence of the causal role of the SLS in
arthritis pathogenesis. Currently, a major mechanism for SLS
dysfunction in RA and OA is associated with inﬂammation. In
synovial tissue, inﬂammatory factors and cells such as macrophages can affect LV cell function. Furthermore, LV cells, including
LECs and lymphatic muscle cells, can be inﬂamed, resulting in
functional changes. It will be very interesting to identify molecular
signatures of LECs and lymphatic muscle cells in an arthritic
microenvironment and discover new pathological genes/pathways that are intrinsically expressed by LV cells.
CONCLUSIONS
Over the past decades, our understanding of OA pathogenesis
has expanded from OA being a ‘wear and tear’ disease to whole
joint pathology featuring synovitis, cartilage damage, subchondral bone remodeling, and osteophyte formation. OA pathology
involves a variety of factors, such as mechanical loading, aging,
inﬂammation and metabolic changes, and the activation of
different signaling pathways, such as Wnt/β-catenin, Ihh, TGF-β,
EGFR, HIF, NF-κB, and Notch. New approaches and novel
techniques have been explored and developed in OA research
from different aspects. Epigenetic regulation, such as DNA
methylation, histone modiﬁcation, and miRNA regulation,
provides new insights into the pathogenesis of OA at the
transcriptional and/or posttranscriptional level. A variety of cell
death types have been observed in OA development and have
signiﬁcant impacts on OA pathology. The synovial lymphatic
system plays an important role in the clearance of cartilagederived catabolic factors in the synovium of OA joints, which
opens up novel research directions. Novel techniques, such as
CRISPR/Cas9 genome editing, single-cell RNA sequencing, and
lineage tracing, have been developed and used in OA studies,
and these techniques greatly facilitates the discovery of new
methods and drug candidates for OA treatment. Despite the
signiﬁcant progress in our understanding of OA pathogenesis,
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Fig. 6 Arthritogenic MMP13 is removed from osteoarthritic and inﬂamed joints via the synovial lymphatic system. C57BL/6J mice received
sham or DMM surgery (a–c), and TNF-Tg and WT control mice (d–f) were used. Knees and DLNs were harvested from operated mice 6 weeks
post-surgery (a–c) and from 6-month-old WT and TNF-Tg mice (d–f). a, d Frozen sections from the knees were H&E stained for light
microscopy, and representative 10x images are shown (scale bar = 100 µm). F: femur, T: tibia, M: meniscus. Parallel knee sections (dotted lines
indicate the joint space) and DLN sections were immunostained with green ﬂuorescent labeled antibodies against MMP13, counterstained
with DAPI, and representative dark ﬁeld images obtained at 10x are shown. Note that only articular chondrocytes in PTOA knees, synovium in
TNF-Tg knees, and their DLNs, have robust MMP13 immuno-reactivity. b, e VisioPharm histomorphometry was performed to quantify the
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non-arthritic control with paired t-test). The content presented in Fig. 6 was derived from a PhD dissertation and was provided by Dr. Xi Lin,
with her permission, a postdoctoral fellow in University of Rochester Medical Center258

the etiology and pathological mechanisms of OA are not yet
fully understood. It is conceivable that the application of novel
techniques could accelerate our understanding of OA pathogenesis. In the future, it will be crucial to explore the molecular
mechanisms underlying OA-associated pain and articular
pathology as well as the relationships between them, which
would be helpful in developing more speciﬁc and effective
therapeutic interventions for OA.
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